Ball Memorial Hospital

Indiana University Health Ball Memorial Department of Research - Open Clinical Trials.

AKEBIA PRO2TECT PI: Unnikrishna Pillai, MD Coordinator - Erin Loomis
Phase 3 Randomized, Open-Label, Active-Controlled clinical study evaluating the Efficacy and Safety of investigational new drug Vadadustat for the Maintenance Treatment of Anemia in Subjects with Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) (PRO2TECT-CONVERSION). Open for enrollment.

APPRAISE-ATP PI: Bruce Graham, MD Coordinator – Sherry Adair
The purpose of this study is to determine which programming arm, antitachycardic pacing followed by defibrillation or defibrillation only, is the best option (safe and efficacious) for this patient population. Open for enrollment.

ARAMIS PI: John D. Wulff, MD Coordinator – Sherry Simmonds
Management of Acute Stroke Patients on Treatment with New Oral Anticoagulants: Addressing real-world Anticoagulant Management Issues in Stroke (ARAMIS) Registry. Open for enrollment.

AWARE JANSSEN PI: Gordon M. Hughes, MD Coordinator – Sherry Adair/Chris Yencer
Comparative and Pragmatic Study of Simponi Aria versus Remicade in Rheumatoid Arthritis, open for enrollment.

CIRT PI: Bruce M. Graham, MD Coordinator – Erin Loomis
Cardiovascular Inflammation Reduction Trial (CIRT): A randomized double-blind, placebo-controlled, event-driven trial of weekly low-dose methotrexate (LDM) in the prevention of cardiovascular events among stable coronary artery disease patients with type 2 diabetes or metabolic syndrome. Open for enrollment.

CONNECT HF PI: Wayne Gray, MD Coordinator – Sherry Adair
Care Optimization through Patient and Hospital Engagement Clinical Trail Heart Failure, it is a hospital based quality improvement (QI) trail, comparing two QI initiatives to usual care on heart failure outcomes and heart failure of car metrics at 1 year after discharge for participants hospitalized with acute heart failure and reduced ejection fraction. Open for enrollment.

GALACTIC PI: Wayne Gray, MD Coordinator – Erin Loomis
The purpose of this study is to evaluate the effect of treatment with omecamtiv mecarbil compared to placebo on the time to cardiovascular death or first heart failure event, whichever may occur first, in subjects with chronic heart failure with reduced ejection fraction receiving standard of care therapy. Open for enrollment.

HEART-FID/FIRE-HF PI: Wayne Gray, MD Coordinator – Sherry Adair/Ali Belangee
Purpose for this study is to determine the safety and effectiveness of iron therapy in patients with heart failure and anemia. Open for enrollment.

INDIANA BIOBANK **PI: Brandon Dickey, MD** **Coordinator – Mona Geinosky**

The purpose of this research study is to obtain a biological sample (e.g., a blood sample) and personal health information located in one place (bank) to conduct research on many diseases and health conditions that affect Hoosiers. Open for enrollment.

PARADISE **PI: Bruce Graham, MD** **Coordinator – Ali Belangee**

The purpose of this study is to test if LCZ696 taken twice a day compared to Ramipril taken twice a day, is safe and effective in reducing complications following an acute myocardial infarction (post-AMI), such as death from cardiovascular (CV) causes, hospitalization for heart failure (HF), or outpatient (HF). Open for enrollment.

PIONEER HF NOVARTIS **PI: Wayne Gray, MD** **Coordinator – Sherry Adair/Chris Yencer**

The purpose of this study is to see if starting sacubitril and valsartan while in the hospital, as compared to Enalapril, will have an effect on the blood test called NT-proBNP, that reflects elevated pressures or stress on the heart, in patients that have been hospitalized for a type of heart failure where the heart is weak and cannot pump enough blood to the lungs and the rest of the body. Open for enrollment.

VICTORIA HF **PI: Wayne Gray, MD** **Coordinator - Ali Belangee**

The primary focus of this study is to evaluate the efficacy of the oral soluble guanylate cyclase (sGC) stimulator MK-1242 (vericiguat) in comparison to placebo on a background of standard of care in increasing the time to first occurrence of the composite of CV (cardiovascular) death or HF (heart failure) hospitalization in subjects with HFrEF (heart failure with reduced ejection fraction). Open for enrollment.